Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Jill Roberts
Another way to know what’s too old to eat
Patricia Santos-Serrao
Four pharma quality trends
Del Williams
Preventing damage caused by large, suspended particles
Kari Miller
An effective strategy requires recruiting qualified personnel familiar with the process and technology

More Features

FDA Compliance News
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community
Good quality is adding an average of 11 percent to organizations’ revenue growth
Further enhances change management capabilities
Creates adaptive system for managing product development and post-market quality for devices with software elements
VQIP allows for expedited review and importation for approved applicants that demonstrate safe supply chains

More News

Sen. Chuck Grassley Press Office

FDA Compliance

Senator Grassley Questions FDA Drug Safety

Published: Tuesday, April 22, 2008 - 22:00

(Washington, D.C.) — Republican senator Chuck Grassley of Iowa has asked for an independent assessment of how the Food and Drug Administration (FDA) follows up on the effects of medicines that it approves based on narrowly defined benefits.

“The way things have turned out with drugs like Vytorin and Avandia raise enough questions that a review is warranted,” says Grassley. “It’s not clear if the FDA’s own policies are being enforced internally, where the agency is supposed to require companies to perform follow-up studies. These policies are designed for patient safety.”

Grassley’s questions stem from a practice of the FDA to use goals called surrogate endpoints to study whether a particular drug achieves a certain benefit such as lowering blood sugar in diabetics. Grassley claims it’s critically important that the agency adhere to its complementary policies that require drug-safety reviewers to follow up on drugs that are approved based on surrogate endpoints.

“The public relies on the FDA to keep it safe from dangerous drugs and not just stick to narrow judgments that may not incorporate overall health,” says Grassley. The diabetes drug Avandia was approved because it lowered blood sugar but later was found to increase the risk of heart attack, even though lower blood sugar is tied to lower heart attack risk.

The government accountability office, which is the investigative arm of Congress, has agreed to conduct the review that Grassley requested.

For further information, visit: http://grassley.senate.gov/public/index.cfm?FuseAction=PressReleases.Detail&PressRelease_id=7bcc065f-ef27-d012-3382-8d1d9ffe2b39&Month=3&Year=2008.


About The Author

Sen. Chuck Grassley Press Office’s default image

Sen. Chuck Grassley Press Office